Amgen (NASDAQ:AMGN) had its price target raised by analysts at Royal Bank Of Canada from $330.00 to $335.00. They now have an "outperform" rating on the stock.
Amgen (NASDAQ:AMGN) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $400.00 to $403.00. They now have a "buy" rating on the stock.
Amgen CEO: There are a bunch of ways to win for patients when it comes to weight loss [CNBC]
Amgen CEO Bob Bradway goes one-on-one with Jim Cramer [CNBC]
Amgen CEO says weight loss drug can address ‘patient persistence issue' [CNBC]